Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $27K fell 96.3% year over year, behind the +328.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 98.1% from the prior quarter. Over 3 fiscal years it compounded at -40.6% a year.

Context

  • Depreciation & amortization amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -96.3% toward the trailing-twelve-month pace of +328.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27K-98.1% QoQ
Last fiscal yearDec 2025
$105K+66.7% YoY
LTMMar 2026
$1.5M+328.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-96.3%——
1 year+66.7%——
3-year CAGR-40.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
105K USD
Year-over-year change
+66.7%
4-year CAGR
-35.6%

Depreciation & Amortization vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +328.5% is the highest of 10, against a peer median of -0.2%.
  • Depreciation & amortization amounts to 0.4% of revenue for ESPR, versus a peer median of 13.9%.
ESPR Competitors
Depreciation & Amortization for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OFIXOrthofix Medical Inc.LTM Mar 2026$136.43M USD+43.1%+37.4%16.5%
EBSEmergent BioSolutions Inc.LTM Mar 2026$93.9M USD-11.7%-12.6%13.9%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
RGNXREGENXBIO Inc.LTM Mar 2026$15.52M USD-3.0%+6.5%17.7%
ABSIAbsci CorporationLTM Mar 2026$11.4M USD-12.6%-3.6%620.8%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$1.5M USD+328.5%-40.6%0.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$577.25K USD+7.8%+2.8%0.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$522K USD-19.7%-38.8%1.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$481K USD+11.1%-33.4%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K USD+33.3%-34.1%—
Peer median (excluding ESPR) —-0.2%-3.6%13.9%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Depreciation & Amortization612K500K164K63K105K
Deferred Income Tax00000
Stock-Based Compensation24.31M15.22M11.96M11.99M9.87M
Change in Working Capital(52.51M)(3.37M)13.68M(60.53M)(14.64M)
Accounts Receivables(10.55M)(10.8M)(14.77M)(31.65M)(60.05M)
Inventory(18.26M)(807K)(30.42M)(28.87M)(10.63M)
Accounts Payables(34.1M)5.6M8.68M12.43M20.92M
Other Working Capital10.39M2.63M50.18M(12.45M)35.12M
Other Non-Cash Items32.89M46.49M47.96M76.57M14.26M
Operating Cash Flow(263.81M)(174.83M)(135.49M)(23.65M)(13.09M)
Capital Expenditures000(317K)0
Acquisitions (Net)00000
Purchases of Investments(50.48M)(59.9M)000
Sales of Investments068M42.5M00
Other Investing Activities00000
Investing Cash Flow(50.48M)8.1M42.5M(317K)0
Debt Repayment(440K)(58.24M)(15.51M)35.01M(54.91M)
Common Stock Issued218.69M90.85M56.88M91.19M98.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities49.98M0(6.42M)(39.72M)(7.26M)
Financing Cash Flow268.22M32.61M50.46M86.48M36.18M
Effect of Forex Changes00000
Net Change in Cash(46.07M)(134.12M)(42.53M)62.51M23.09M
Free Cash Flow(263.81M)(174.83M)(135.49M)(23.97M)(13.09M)

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.